MA Application for Biosimilars
In the EC, technologically advanced medicinal products such as products developed by means of a biotechnological process (e.g. recombinant DNA technology) can be placed on the market only after a MA has been issued by the EC in accordance with the provisions of Regulation (EC) No. 726/04 [1] (centralized procedure). The centralized EC authorization was introduced in 1993, in order to maintain the high level of scientific evaluation and to preserve the confidence of patients and the medical professions in the evaluation process.
The application must be accompanied by a dossier containing the required data, presented in accordance with a standardized format, namely the Common Technical Document. The CTD is composed of five modules: Module 1 provides specific administrative data, Module 2 provides quality, non-clinical and clinical summaries, Module 3 provides chemical, pharmaceutical and biological information (quality), Module 4 provides non-clinical reports (safety), and Module 5 provides clinical study reports (efficacy) [2] .
When patent rights, supplementary protection certificates and a relevant period of data protection (a 10-or 11-year period) expire, it seems unethical and uneconomical to ask other applicants to provide a full dossier for a copy of that particular medicinal product. Hence in the case of a copy of a small-molecule chemical entity (generics) , the applicant is not required to provide the results of preclinical tests and clinical trials if it is possible to demonstrate that the copy contains the same active substance(s) as that of a reference medicinal product authorized in the EC over a period longer than 8 years, and a bioequivalence demonstrated through appropriate bioavailability studies.
In the case of the copy of a biological medicinal product, the active substances are similar but not identical to the ones in the innovator product, due to the strong relationship between the manufacturing processes of biopharmaceuticals and the characteristics of the final product. Moreover, since no analytical techniques are currently available for detecting or predicting all biological and clinical properties of proteins, differences between biopharmaceutical products can easily remain undetected [3] .
If the copy of a biological medicinal product does not meet the conditions in the definition of generic medicinal products, the requirements for MA applications are based on the demonstration of the similar nature of the two biological products through comparability studies, named the 'comparability exercise'. The comparability exercise is needed to generate evidences substantiating the similar nature in terms of quality, safety and efficacy of the new similar biological medicinal product and the chosen reference medicinal product authorized in the EC [4] .
The number and extent of comparability studies required for granting a MA are detailed in guidelines issued by EMEA's Committee for Medicinal Products for Human Use (CHMP). These guidelines cover a range of issues including manufacturing, demonstration of comparability for quality (Module 3), non-clinical (Module 4) and clinical study (Module 5) reports, physicochemical and biological analyses and clinical trial requirements, and additional data (i.e. toxicological and other non-clinical and appropriate clinical data) whose relevance has to be determined on a case-by-case basis, due to the complexity and diversity of the products. The purpose is to demonstrate the similar nature of the biosimilar and the reference product in terms of quality, safety and efficacy.
Regulatory Policy: EMEA Guidelines
The comparability exercise has been introduced by the Food and Drug Administration (FDA) to allow manufacturers of 'biopharmaceuticals well-characterized products', i.e. proteins whose identity, purity, impurities, potency and quantity can be determined and controlled, to implement changes in the manufacturing process -such as change in manufacturing site, or modification to cell and seed strains, or fermentation and purification processes -without conducting additional clinical trials to demonstrate efficacy.
Afterwards, in 2000 and 2002, EMEA issued two guidelines on comparability of medicinal products containing biotechnology-derived proteins as active substance after a change in manufacturing process. Subsequently, EMEA broadened their scope to medicines Additional product-class specific guidelines on preclinical and clinical studies have been developed for a number of therapeutic proteins, such as rHuEPO, providing guidance on appropriate pharmacodynamic and toxicological studies (in the non-clinical section), and on pharmacodynamic, pharmacokinetic, efficacy and safety studies (in the clinical section).
It is clear that the dossier for a biosimilar is much more cumbersome than that of a generic medicinal product, since it comprises at least full Modules 1 and 2, a full Module 3 including the Comparability exercise, and Modules 4 and 5 which consist of the Comparability exercise ( table 1 ) .
In March 2006, EMEA published a Guidance on Similar Medicinal Products containing Recombinant Erythropoietins [6] as an Annex to Guideline on Similar Biological Medicinal Products containing BiotechnologyDerived Proteins as Active Substance: Non-Clinical and Clinical Issues.
In 2008, the experience gained with epoetin alpha biosimilar products has prompted the development of a new guideline [7] , currently in draft, which revises some critical aspects.
Concerning clinical safety, the use of a validated, highly sensitive antibody assay, able to detect both early and late immune responses, is now mandatory. The development of neutralizing antibodies and pure red cell aplasia (PRCA) are taken into account as a major potential safety concern, since they are unlikely to be captured premarketing, due to their rarity. Moreover, since the SC route is usually more immunogenic than the IV and patients with renal anemia constitute the population at risk for developing anti-epoetin antibody-induced PRCA, the immunogenicity database should include a sufficient number of SC-treated patients with renal anemia, unless SC use in this population is not applied for.
No changes regard the feasibility of extrapolation to other indications of the reference medicinal product as long as it is applied to the same route of administration. Moreover, the clinical efficacy has to be demonstrated with at least two adequately powered, randomized, parallel group clinical trials while in the proposed draft the number of clinical trials is not specified.
In the new guideline, similar efficacy between the test and the reference product should be ensured for both the IV and SC routes of administration, either by performing separate clinical trials for both routes or by performing one clinical trial for one route and providing adequate bridging data for the other route (new possibility). In our opinion, this new possibility is a matter of concern. To the best of our knowledge, not a clear single case of PRCA has been reported using rHuEPO administered only by IV, being all the reported cases of PRCA associated with the SC use of rHuEPO or with the use SC and IV in the same patient. Thus, while it could be possible to translate the safety information related to the risk of PRCA (and possibly of other immunological side effects) from the experience with the SC to the IV route of administration, the other side around, that is to translate the safety information collected in trials using rHuEPO only IV to the SC route of administration, would rise great safety concerns.
FDA's Perspective on Biosimilars
At present the EMEA guidelines are the only clear regulatory effort concerning biosimilars (called follow-on proteins in the USA) worldwide. However, now that patent rights of many biotechnological originators are likely to expire in the USA, more in-depth regulation about copy drugs will be needed also in this country. To this end, EMEA's regulatory experience represents an important reference for the new policy on biosimilars that the FDA is expected to develop in the near future.
It must be reminded though that there are significant differences in the regulatory frameworks of biological medicines in the USA and Europe. FDA has different ( table 2 ) .
Thus, FDA's viewpoint seems to be that only in the case of relatively simple peptide or protein products (already regulated under the FDC Act), technology has progressed to the point where it is becoming possible to assess the degree of similarity between the innovator and a follow-on product, and an abbreviated pathway can be envisaged (a new authority for the FDA to approve followon biologics has been proposed in FDA's Fiscal Year 2010 Budget [9] ). The same does not hold true for biologic products, because of the complexity of manufacturing and characterizing a biologic. Thus, the PHS Act emphasizes the importance of appropriate manufacturing control for products and it has no provision for an abbreviated route [10, 11] .
Critical Aspects of Medicinal Products Containing rHuEPO

Safety and Efficacy
The introduction of similar biological medicinal products into clinical practice presents new challenges, due to the potential impact on patient safety. This is particularly true in the case of rHuEPO, the only glycosylated protein contained in authorized biosimilar products so far. Indeed, a number of PRCA cases have been described in patients receiving SC biosimilar of epoetin alpha manufactured outside the EC [12, 13] .
Five products containing rHuEPO, biosimilar of the reference product Eprex/Erypo (epoetin alpha, Janssen-Cilag GmbH), have been approved by the EMEA ( table 3 ): -Abseamed , Binocrit and Epoetin alfa Hexal are epoetin alpha products, all of them produced by Rentschler Biotechnologie, GmbH (HX575), but marketed by three different companies. Comparability exercises demonstrated that the isolated active substance 'is representative of the active substance present in the reference medicinal product' and the analysis of the protein part did not reveal any significant difference with the reference product. Differences were observed at the glycosylation level: phosphorylated high mannose type structures in the biosimilar products were detected at higher levels than in Eprex/Erypo. However, they are considered to be common glycoforms of recombinant erythropoietins and their presence is described in the literature for other recombinant cytokines and a large variety of non-lysosomal proteins from human plasma and they do not impact on efficacy or safety. In addition, neuraminic acid differences were observed. However, biosimilar drug substance showed lower values of N-glycolyl-neuraminic acid [15] . It has also been reported that the protein content of Eprex is higher than that of Retacrit [16] . The clinical implications of these small molecular differences are still unknown.
Naming
The approach used so far by the WHO for EPO-based products, consists of: (1) identification of the group with the stem -poetin , (2) indication of differences in the amino acid chain by using a random prefix, and (3) indication of differences in the glycosylation pattern by a Greek letter added as second word to the name (e.g. epoetin alpha ).
According to this scheme, 10 INNs have been assigned to rHuEPO and its derivates to date: darbepoetin alpha , epoetin alpha , epoetin beta , epoetin gamma , epoetin delta , epoetin epsilon , epoetin zeta , epoetin theta , epoetin kappa , epoetin omega [17] .
It is important to emphasize that the choice of INNs of biotechnology medicines is closely linked to the issue of substitution and interchangeability.
Substitution and Interchangeability
Interchangeability follows from therapeutic equivalence and is related to intrinsic drug characteristics. In contrast, a substitution program can be introduced by the Public Administration on the basis of interchangeability and is related to administrative procedures than can be implemented differently in different Member States. The term 'substitution' here means 'automatic substitution' at the dispensing level, without prejudice to the freedom the physicians has to change a prescription on the basis of his knowledge and clinical data.
The originator drug and its biosimilar products (or biosimilar products from different manufacturers) are not interchangeable as bioequivalence cannot be used to demonstrate therapeutical equivalence, and the active substance is similar but not identical between the two products. Thus, automatic substitution at the dispensing level, without the physician's knowledge or explicit prior consent, should not be permitted, since, apart from clinical concerns, it may lead to difficulties in monitoring safety profiles of products compromising pharmacovigilance programs. Moreover, frequent changes in administered molecules may increase immunogenicity of these drugs. However, in the area of substitution, the European Union (EU) leaves a broad margin of discretion, giving each Member State the faculty to set substitution policies, which follows very strict rules in most cases (e.g. in France, Spain, Italy).
In many Member States, if the prescription specifies only the INN, the pharmacy may dispense any product with that INN or indeed any of a group of products deemed therapeutically equivalent or generically substitutable. Since this approach is clearly inadequate for biological medicinal products, the need emerges to reduce patient safety risks associated with switching from one product to another without the treating physician's knowledge and permission. The safety and efficacy of biological medicinal products are highly dependent on a variety of factors, including the product's manufacturing processes and formulation. Although this is particularly true with glycosylated proteins, there are concerns with all recombinant protein drug substances [18, 19] .
Cost
One of the main benefits of biosimilars should be a reduced cost compared with their respective innovator products. Nevertheless, savings cannot be expected to be in the same order of magnitude as in the case of generics, due to high manufacturing costs, the need to perform reduced non-clinical and clinical studies, and an appropriate pharmacovigilance program. As an example, in the UK the list prices of four biosimilars (Omnitrope , Binocrit, Retacrit, and Ratiograstim ) compared with their respective innovator products are about 10-25% less [20] .
Conclusions
Biological medicinal products are very complex molecules and present a specific public health and safety challenge that is not ordinarily presented by synthetic Minghetti /Rocco /Del Vecchio /Locatelli Nephron Clin Pract 2011;117:c1-c7 c6 medicines. Guaranteeing consistency in the production of these agents has already proved difficult. Incidences such as the increased occurrence of PRCA cases in 1998 demonstrated how one small subtle change in the manufacturing process can alter the product's characteristics. In light of this upsurge in cases of PRCA, which has been linked to several possible causes including a small, deliberate change in the formulation of one brand of erythropoietin-stimulating agent, there is increased concern about the potential of slight molecular differences to have significant immunogenic consequences [21] .
Thus, it is important to be aware that biotechnological medicinal products, including biosimilars, may be unfortunately associated with rare adverse events, or medically significant increases in such events, that cannot be detected through any reasonable course of premarket testing. It is therefore essential that adverse events with biological products be attributable to the correct product and that inappropriate substitution is avoided. We would like to underline that this is true not only for all the bio similars but also for all the originators and that substitution of a biosimilar for either an originator or another biosimilar should be approached with great caution.
